This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Low-Grade Glioma industry.
What is the current market size of the low-grade glioma industry, and what growth rate is it expected to achieve?
The low-grade glioma market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.48 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to growth in awareness of brain tumors, increased funding in oncology spurred research, an increase in orphan drug designations, the expansion of telemedicine, and an increase in healthcare access.
The low-grade glioma market size is expected to see strong growth in the next few years. It will grow to $1.86 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to a rising aging population, rising healthcare expenditure, increasing prevalence of brain tumors, growing government initiatives, and a rise in the incidence and prevalence of high-grade gliomas. Major trends in the forecast period include advancements in imaging technologies, development of radiation therapies, introduction of chemotherapy regimens, clinical trials expansion, and the integration of immunotherapy.
Download Your Free Sample PDF:
What are the major drivers contributing to the growth of the low-grade glioma market?
The rising incidence of brain tumors is expected to propel the growth of the low-grade glioma market going forward. A brain tumor is an abnormal growth of cells in the brain or surrounding areas, which can be benign or malignant. The rising incidence of brain tumors is due to factors such as increased exposure to radiation, environmental pollutants, genetic predisposition, and aging. Low-grade glioma is helpful for brain tumors by utilizing advanced diagnostic techniques and targeted therapies such as surgery, radiation, and chemotherapy, which help slow tumor progression, preserve neurological function, and improve patient outcomes, making early detection and personalized treatment crucial for managing other brain tumors with similar growth patterns. For instance, in October 2023, according to The Central Brain Tumor Registry of the United States (CBTRUS), a US-based not-for-profit organization, in 2022, the worldwide incidence of primary malignant brain tumors was approximately 3.5 per 100,000, with higher rates in high-income countries (4.9 per 100,000) compared to low-middle (2.4 per 100,000) and low-income countries. Therefore, the rising incidence of brain tumors is driving the growth of the low-grade glioma market.
What are the major market segments driving the growth of the low-grade glioma industry?
The low-grade glioma market covered in this report is segmented –
1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib
2) By Treatment: Surgery, Chemotherapy, Radiation
3) By Route Of Administration: Topical, Oral
4) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
View The Full Market Report:
What are the top market trends driving innovation in the low-grade glioma industry?
Major companies operating in the low-grade glioma market are focusing on the integration of combination therapies and targeted therapy, such as genetic alteration drugs, to gain a competitive edge and enhance the treatment of children with low-grade glioma. Genetic alteration drugs are targeted therapies designed to modify or inhibit specific genetic mutations or abnormalities in cells, helping to treat diseases such as cancer by blocking the pathways that drive uncontrolled cell growth. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, launched Tovorafenib (Ojemda) after receiving accelerated FDA approval. This targeted therapy is designed for children aged six months and older with unresectable or recurrent low-grade glioma (LGG) with BRAF gene alterations. Offering a convenient once-weekly oral treatment, it addresses a crucial need for pediatric LGG patients with limited prior treatment options.
Who are the key market players contributing to the growth of the low-grade glioma industry?
Major companies operating in the low-grade glioma market are McKesson Corporation, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Daiichi Sankyo Company Limited, Ipsen S.A., BeiGene Ltd., NovoCure Limited, Les Laboratoires Servier, Day One Biopharmaceuticals Inc., CStone Pharmaceuticals Co. Ltd., AnHeart Therapeutics Inc., Apollomics Inc., Agios Pharmaceuticals Inc., BioMed Valley Discoveries Inc., Avistone Biotechnology Co. Ltd., NextSource Biotechnology LLC, Sunesis Pharmaceuticals Inc.
Which regions are leading the growth of the low-grade glioma market globally?
North America was the largest region in the low-grade glioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Low-Grade Glioma Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Low-Grade Glioma Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment